Jul 11, 2024
In this episode, host Shikha Jain, MD, speaks
with Komal Jhaveri, MD, about breakthroughs in
breast cancer treatment, where the field is evolving with anti-body
drug conjugates and more.
• Welcome to another exciting episode of Oncology
Overdrive 1:17
• About Jhaveri 1:21
• The interview 1:41
• How did you get into this highly specialized field?
[…] How did you become a breast oncologist and find yourself at
Memorial Sloan Kettering? 2:07
• As a breast oncologist, what has really excited you
in the breast cancer space over the last decade?
5:02
• What do you think is going to happen in the next
five to twenty years? Where do you think breast cancer treatment is
going to evolve? 13:44
• Do you think AI is going to have a big impact on how
we treat patients? 17:47
• If someone could only listen to the last minute of
this episode, what would you want them to take away?
19:52
• How to contact Jhaveri
20:34
• Thanks for listening
21:32
Komal Jhaveri, MD, is a breast oncologist & early
drug development specialist, clinical director of the early drug
development service, and section head of the endocrine therapy
research program at Memorial Sloan Kettering Cancer Center
(MSK).
We’d love to hear from you! Send your comments/questions to Dr.
Jain at oncologyoverdrive@healio.com.
Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/.
Follow Dr. Jain on X:
@ShikhaJainMD. Jhaveri can be reached at her office
646-888-5157, or via email jhaverik@mskcc.org.
Disclosures: Jain reports no relevant financial
disclosures. Jhaveri reports she is the principal investigator for
Genentech’s INAVO120 trial at MSK and co-chair globally.